“European researchers report [at the 2009 American Society of Clinical Oncology Annual Meeting being held in Orlando, Florida from May 29 through June 2nd] that starting treatment early for an ovarian cancer relapse based on CA125 blood levels alone does not improve overall survival, compared with delaying treatment until symptoms arise.”

Continue reading →